Etoricoxib in the treatment of chronic pain.
For the many patients who suffer chronic pain, we seek the most effective anti-inflammatory drug with the least side-effect profile and the greatest long-term safety. Etoricoxib, a selective COX2 inhibitor, has been shown to be as effective as non-selective non-steroidal anti-inflammatory drugs in the management of chronic pain in rheumatoid arthritis and osteoarthritis, for periods of up to one year. Data on etoricoxib efficacy in chronic low back pain is beginning to emerge. The side-effect profile of etoricoxib suggests it is well tolerated with similar adverse effects to non-selective NSAIDs. Larger studies are awaited, to see whether superior gastrointestinal tolerability can be proven. Further work will be required to show that etoricoxib is safe in patients with pre-existing cardiovascular or gastrointestinal comorbidity, and the potentially confounding role of aspirin still needs to be elucidated. However, etoricoxib shows promise as a new and effective COX2 inhibitor in clinical practice.
Duncan
M R
MR
Centre for Rheumatic Diseases, Royal Infirmary, Glasgow G4 0SF, UK.
Capell
H A
HA
D000328:Adult; D000368:Aged; D001168:Arthritis / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D004311:Double-Blind Method; D000077613:Etoricoxib; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D017116:Low Back Pain / Q000188:drug therapy; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy*; D011725:Pyridines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013450:Sulfones / Q000627:therapeutic use*
D016861:Cyclooxygenase Inhibitors; D011725:Pyridines; D013450:Sulfones; D000077613:Etoricoxib